NRL-1004

NRL-1004 is an investigational, proprietary intranasal spray formulation of olanzapine developed by Neurelis for the acute treatment of agitation episodes associated with schizophrenia and bipolar disorder. The product utilizes Intravail®, a transmucosal absorption enhancement technology, to enable rapid and noninvasive delivery of olanzapine via the nasal route. This approach aims to provide a portable, immediate-use medication option for patients outside medical settings, potentially reducing emergency room visits for individuals experiencing acute agitation. As of 2025, NRL-1004 has completed Phase 1 clinical trials but has not been approved by the U.S. Food and Drug Administration for any indication[1][2][3][5][9].

Other names

olanzapine intranasal sprayintranasal olanzapine